Business Description
Alpa Laboratories Ltd
ISIN : INE385I01010
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 48.91 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | 0.08 | |||||
Interest Coverage | 23.71 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 5.92 | |||||
Beneish M-Score | -2.25 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.8 | |||||
3-Year EBITDA Growth Rate | 24 | |||||
3-Year EPS without NRI Growth Rate | 16.7 | |||||
3-Year FCF Growth Rate | 17.7 | |||||
3-Year Book Growth Rate | 12.2 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 85.87 | |||||
9-Day RSI | 70.07 | |||||
14-Day RSI | 60.15 | |||||
6-1 Month Momentum % | 39.94 | |||||
12-1 Month Momentum % | 17.07 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.55 | |||||
Quick Ratio | 5.09 | |||||
Cash Ratio | 3.46 | |||||
Days Inventory | 80.86 | |||||
Days Sales Outstanding | 154.8 | |||||
Days Payable | 106.49 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -0.77 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 36.07 | |||||
Operating Margin % | 9.45 | |||||
Net Margin % | 21.59 | |||||
FCF Margin % | -2.84 | |||||
ROE % | 13.59 | |||||
ROA % | 11.05 | |||||
ROIC % | 10.81 | |||||
ROC (Joel Greenblatt) % | 61.98 | |||||
ROCE % | 17.4 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 11.76 | |||||
PE Ratio without NRI | 16.48 | |||||
Shiller PE Ratio | 27.67 | |||||
Price-to-Owner-Earnings | 18.85 | |||||
PEG Ratio | 0.47 | |||||
PS Ratio | 2.55 | |||||
PB Ratio | 1.49 | |||||
Price-to-Tangible-Book | 1.51 | |||||
Price-to-Operating-Cash-Flow | 67.47 | |||||
EV-to-EBIT | 5.37 | |||||
EV-to-EBITDA | 4.95 | |||||
EV-to-Revenue | 1.5 | |||||
EV-to-FCF | -46.49 | |||||
Price-to-Projected-FCF | 1.83 | |||||
Price-to-DCF (Earnings Based) | 0.63 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.66 | |||||
Price-to-Graham-Number | 1.05 | |||||
Price-to-Net-Current-Asset-Value | 1.73 | |||||
Price-to-Net-Cash | 3.25 | |||||
Earnings Yield (Greenblatt) % | 18.64 | |||||
FCF Yield % | -1.08 | |||||
Forward Rate of Return (Yacktman) % | 21.51 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Alpa Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ₹) | 964.768 | ||
EPS (TTM) (₹) | 9.95 | ||
Beta | 1.4 | ||
Volatility % | 50.54 | ||
14-Day RSI | 60.15 | ||
14-Day ATR (₹) | 3.992322 | ||
20-Day SMA (₹) | 111.487 | ||
12-1 Month Momentum % | 17.07 | ||
52-Week Range (₹) | 69.9 - 144.5 | ||
Shares Outstanding (Mil) | 21.04 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 7 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Alpa Laboratories Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Alpa Laboratories Ltd Stock Events
Event | Date | Price(₹) | ||
---|---|---|---|---|
No Event Data |
Alpa Laboratories Ltd Frequently Asked Questions
What is Alpa Laboratories Ltd(NSE:ALPA)'s stock price today?
When is next earnings date of Alpa Laboratories Ltd(NSE:ALPA)?
Does Alpa Laboratories Ltd(NSE:ALPA) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |